Invivyd (NASDAQ:IVVD) Earns “Buy” Rating from HC Wainwright

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 373.93% from the company’s previous close. HC Wainwright also issued estimates for Invivyd’s FY2029 earnings at $0.41 EPS.

Several other research analysts have also weighed in on IVVD. Morgan Stanley cut their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Invivyd in a report on Monday. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $7.89.

Invivyd Stock Up 68.8 %

NASDAQ:IVVD opened at $2.11 on Tuesday. The company has a market cap of $252.40 million, a P/E ratio of -1.08 and a beta of 0.61. The firm’s 50 day moving average is $0.52 and its two-hundred day moving average is $0.82. Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $5.10.

Insider Transactions at Invivyd

In related news, Director Terrance Mcguire sold 150,000 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00. Following the transaction, the director now directly owns 4,538,079 shares of the company’s stock, valued at approximately $2,768,228.19. The trade was a 3.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders sold 816,466 shares of company stock valued at $423,214 over the last quarter. Company insiders own 17.90% of the company’s stock.

Institutional Trading of Invivyd

A number of hedge funds have recently made changes to their positions in IVVD. Renaissance Technologies LLC acquired a new stake in Invivyd during the 2nd quarter valued at $421,000. Barclays PLC increased its position in shares of Invivyd by 179.6% during the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after acquiring an additional 75,780 shares during the last quarter. Cubist Systematic Strategies LLC lifted its stake in shares of Invivyd by 66.1% in the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after acquiring an additional 53,499 shares in the last quarter. State Street Corp lifted its stake in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in Invivyd by 4.2% during the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after purchasing an additional 31,992 shares in the last quarter. Hedge funds and other institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.